CorMedix IncNASDAQ:CRMD
- LAST PRICE11.2806
- TODAY'S CHANGE (%)-0.7594 (-6.3073%)
- Bid / Lots11.2800/ 2
- Ask / Lots11.3100/ 7
- Open / Previous Close12.0400 / 12.0400
- Day Range
- 52 Week Range
- Volume408,394
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRMD |
|---|---|---|
| 09:32 ET | 21958 | 12.0137 |
| 09:33 ET | 7205 | 11.8745 |
| 09:35 ET | 2622 | 12 |
| 09:37 ET | 5950 | 11.98 |
| 09:39 ET | 6600 | 11.9612 |
| 09:42 ET | 416 | 12.005 |
| 09:44 ET | 2568 | 12.001 |
| 09:46 ET | 9431 | 11.88 |
| 09:48 ET | 1500 | 11.91 |
| 09:50 ET | 6651 | 12.0099 |
| 09:51 ET | 8464 | 11.95 |
| 09:53 ET | 100 | 11.95 |
| 09:55 ET | 100 | 11.95 |
| 09:57 ET | 11131 | 11.875 |
| 10:00 ET | 440 | 11.8571 |
| 10:02 ET | 718 | 11.85 |
| 10:04 ET | 9275 | 11.8175 |
| 10:06 ET | 10844 | 11.78 |
| 10:08 ET | 2227 | 11.775 |
| 10:09 ET | 1095 | 11.7965 |
| 10:11 ET | 6266 | 11.7342 |
| 10:13 ET | 4642 | 11.71 |
| 10:15 ET | 11382 | 11.715 |
| 10:18 ET | 12636 | 11.75 |
| 10:20 ET | 2729 | 11.705 |
| 10:22 ET | 2126 | 11.715 |
| 10:24 ET | 15257 | 11.63 |
| 10:26 ET | 13397 | 11.63 |
| 10:27 ET | 4852 | 11.6403 |
| 10:29 ET | 46972 | 11.585 |
| 10:31 ET | 1016 | 11.564 |
| 10:33 ET | 2889 | 11.5599 |
| 10:36 ET | 20563 | 11.485 |
| 10:38 ET | 17241 | 11.355 |
| 10:40 ET | 7409 | 11.37 |
| 10:42 ET | 13882 | 11.39 |
| 10:44 ET | 1400 | 11.385 |
| 10:45 ET | 5902 | 11.36 |
| 10:47 ET | 1980 | 11.4 |
| 10:49 ET | 10085 | 11.4 |
| 10:51 ET | 4300 | 11.44 |
| 10:54 ET | 12315 | 11.4 |
| 10:56 ET | 2956 | 11.37 |
| 10:58 ET | 1801 | 11.3503 |
| 11:00 ET | 4159 | 11.3265 |
| 11:02 ET | 12743 | 11.2806 |
Nov 4, 2024
CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium, from 8:30AM ET on Monday Nov 04, 2024 by Dow Jones
8:30AM ET on Monday Nov 04, 2024 by Dow Jones
Oct 31, 2024
DJ CorMedix Is Maintained at Buy by Needham, from 6:21AM ET on Thursday Oct 31, 2024 by Dow Jones
6:21AM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 30, 2024
DJ CorMedix Down Over 15%, On Pace for Largest Percent Decrease Since June 2023 -- Data Talk, from 11:56AM ET on Wednesday Oct 30, 2024 by Dow Jones
11:56AM ET on Wednesday Oct 30, 2024 by Dow Jones*DJ CorMedix 3Q Loss/Shr 5c >CRMD, from 7:30AM ET on Wednesday Oct 30, 2024 by Dow Jones
7:30AM ET on Wednesday Oct 30, 2024 by Dow JonesCorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update, from 7:30AM ET on Wednesday Oct 30, 2024 by Dow Jones
7:30AM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CorMedix Inc | 730.6M | -14.1x | --- |
Zevra Therapeutics Inc | 471.5M | -5.2x | --- |
Elite Pharmaceuticals Inc | 577.9M | 29.1x | --- |
Cipla Ltd | 14.9B | 0.0x | --- |
Eton Pharmaceuticals Inc | 250.9M | -35.5x | --- |
Incannex Healthcare Inc | 51.9M | -2.7x | --- |
Company Information
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Contact Information
- Headquarters
- 300 Connell Drive, Suite 4200BERKELEY HEIGHTS, NJ, United States 07922
- Phone
- 908-517-9500
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Myron Kaplan
- Director
- Joseph Todisco
- Chief Financial Officer, Executive Vice President
- Matthew David
- Executive Vice President, Chief Clinical Strategy and Operations Officer
- Elizabeth Massonhurlburt
- Executive Vice President, Chief Legal Officer and Corporate Secretary
- Beth Kaufman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $730.6M |
|---|---|
Revenue (TTM) | $12.3M |
Shares Outstanding | 60.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.60 |
EPS | $-0.80 |
Book Value | $1.28 |
P/E Ratio | -14.1x |
Price/Sales (TTM) | 59.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -415.59% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
